TARE may substitute surgical resection for initial treatment of large single nodular HCC January 6, 2022Hepatocellular Carcinoma
Utilization of AFP to predict HCC recurrence after liver transplantation in waitlisted patientsJanuary 6, 2022Hepatocellular Carcinoma
Whole blood viscosity as a biomarker for distant metastasis and survival in HCCJanuary 6, 2022Hepatocellular Carcinoma
Radiologic response to TACE-RT as a prognostic factor in advanced HCC with macroscopic vascular invasionJanuary 6, 2022Hepatocellular Carcinoma
Atezolizumab + bevacizumab shows long-term benefits over sorafenib for unresectable HCC January 6, 2022Hepatocellular Carcinoma
No survival benefits with first-line nivolumab vs sorafenib in advanced HCCJanuary 6, 2022Hepatocellular Carcinoma
Lenvatinib tops sorafenib for progression-free survival in HCCNovember 15, 2021Hepatocellular Carcinoma
Transarterial chemoembolization plus percutaneous microwave ablation optimizes outcomes for unresectable HCCNovember 15, 2021Hepatocellular Carcinoma
Reduction hepatectomy plus multidisciplinary therapy improves HCC outcomesNovember 15, 2021Hepatocellular Carcinoma
Atezolizumab plus bevacizumab benefits subset of HCC patients as first-line therapyNovember 15, 2021Hepatocellular Carcinoma
Complete response after TACE predicts survival for new HCC patientsNovember 15, 2021Hepatocellular Carcinoma
Neutrophil ratios predict survival in HCC patients after SBRTNovember 15, 2021Hepatocellular Carcinoma
Fevers following radiofrequency ablation for HCC strike soon after procedureNovember 15, 2021Hepatocellular Carcinoma
